Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Granisetron Hydrochloride 0.2-mg/mL Oral Suspension

Author(s):  Allen Loyd V Jr

Issue:  Sep/Oct 2011 - Volume 15, Number 5
View All Articles in Issue

Page(s):  419

Granisetron Hydrochloride 0.2-mg/mL Oral Suspension Page 1

Download in electronic PDF format for $75

Abstract:  A formulation for preparing Granisetron Hydrochloride 0.2-mg/mL Oral Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords: Loyd V. Allen Jr., PhD, RPh, formulation, granisetron hydrochloride, selective type 3 serotonergic blocker, 5-HT3 receptor antagonist, serotonin receptor inhibitor, antiemetic agent, postoperative nausea, vomiting, cancer chemotherapy

Related Categories: CANCER AND AIDS, FORMULATIONS, GASTROENTEROLOGY, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Granisetron Hydrochloride 0.2-mg/mL Oral Suspension
Allen Loyd V Jr
Sep/Oct 2011
Pg. 419

Granisetron 1-mg/mL Injection
Allen Loyd V Jr
Jan/Feb 2013
Pg. 66

Granisetron Hydrochloride 005 mg/mL in Ora-Sweet and Ora-Plus
Allen Loyd V Jr
Nov/Dec 2022
Pg. 513

Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride
Wu George
, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly
Jan/Feb 2018
Pg. 86-94

Granisetron 0.05-mg/mL Oral Suspension
Allen Loyd V Jr
May/Jun 2006
Pg. 222

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Ondansetron Hydrochloride 2-mg/mL Injection
Allen Loyd V Jr
Jul/Aug 2012
Pg. 339

Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration
Trusley Craig
, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
Mar/Apr 2008
Pg. 156-160

Basics of Compounding for Cough
Allen Loyd V Jr
Nov/Dec 2004
Pg. 462-465

Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride
Wu George
, Yeung Stanley, Chen Frank
Jan/Feb 2017
Pg. 76-82

Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C
, Ben Michel, Trusley Craig, Trissel Lawrence A
Mar/Apr 2008
Pg. 170-173

Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration
Trissel Lawrence A
, Xu Quanyun A
May/Jun 2005
Pg. 238-241

Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson
, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Nov/Dec 2018
Pg. 516-526

Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection
Wu George
, Powers Dan, Yeung Stanley, Chen Frank
Jan/Feb 2018
Pg. 76-85

Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration
Ben Michel
, Kupiec Thomas C, Trusley Craig, Trissel Lawrence A
Sep/Oct 2008
Pg. 460-462

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286

Ondansetron Hydrochloride 0.8 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
Jan/Feb 2020
Pg. 60

High-Performance Liquid Chromatographic Method Optimization for Ondansetron Assay in Extemporaneous Topical Gel and in Marketed Products
Quamrun Masuda
, Mamoon Rashid, Nasheed Shams, Mullins Randy
Nov/Dec 2014
Pg. 520-525

Sumatriptan 5-mg or 20-mg per 100-μL Nasal Spray
Allen Loyd V Jr
Mar/Apr 2016
Pg. 147

Return to Top